fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Positive CHMP opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma – BMS

Written by | 6 Feb 2025

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the  EMA has recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the… read more.

Imfinzi (durvalumab) + Imjudo (tremelimumab) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA phase III trial – AstraZeneca

Written by | 22 Sep 2024

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for… read more.

Opdivo + Yervoy significantly improved overall survival compared to lenvatinib or sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma in CheckMate -9DW trial – BMS

Written by | 10 Jun 2024

Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.

CheckMate-9DW trial evaluating Opdivo (nivolumab) + Yervoy (ipilimumab) meets primary endpoint of overall survival for the first-line treatment of advanced hepatocellular carcinoma – BMS

Written by | 24 Mar 2024

Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who… read more.

Sugar-sweetened drinks appear to raise risk of liver cancer and chronic liver disease in women

Written by | 13 Aug 2023

Postmenopausal women who consume one or more sugar sweetened beverage daily appear to have a significantly higher risk of developing liver cancer and chronic liver disease than women… read more.

Imfinzi + Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA phase III trial – AstraZeneca

Written by | 13 Jul 2023

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for… read more.

Novel AI blood test detects liver cancer

Written by | 22 Nov 2022

A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now… read more.

Researchers develop optical biopsy system that detects liver cancer

Written by | 20 Jan 2022

New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.

Study introduces new strategy to treat advanced liver cancer

Written by | 19 Nov 2021

Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by… read more.

External-beam radiation therapy underused for people with liver cancer awaiting transplant

Written by | 6 Nov 2021

First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.

Phase III KEYNOTE-394 trial of Keytruda meets primary endpoint in hepatocellular carcinoma – Merck Inc

Written by | 6 Oct 2021

Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.

Drug for common liver condition may be an effective treatment for dementia

Written by | 3 Oct 2020

A drug used to treat cirrhosis of the liver may be an effective treatment for a form of Dementia and motorneuron disease, scientists have discovered. The research, led… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.